Study of some immune aspects in patients with fascioliasis before and after Chommiphora molmol (Mirazid) treatment.
This study was planned to evaluate the in vitro production of IL-1 beta and IL-4 by peripheral blood mononuclear cells (PBMCs) and total IgE in patients with fascioliasis before and 3 months after treatment with purified extract of myrrh from Commiphora molmol tree (Mirazid), to determine the role of these variables in immunopathogenesis of the disease in relation to this new drug. The study was carried out in Departments of Tropical Medicine, Al-Azhar University Hospitals in the period from March 2002 to November 2003. A total of 35 patients with chronic fascioliasis with age range from 9-45 years in addition to 10 healthy subjects with matched age and sex serving as controls were studied. Serum IgE and in vitro IL-1 and IL-4 were estimated by enzyme immuno-assay (ELISA) before and 3 months after therapy. Results revealed significant increase in IL-1 beta in patients before treatment than control (p<0.001) but it decreased significantly after therapy (p<0.001) to reach the control level (p=0.16). In contrast, IL-4 was significantly lower than control before therapy (p=0.04) and increased significantly after treatment (p<0.001) to reach normal levels as control (p=0.59). Total IgE was significantly elevated in patients before treatment (p<0.001) and it did decrease significantly with treatment (p<0.001), although it remained significantly higher than the control level. In conclusion, Mirazid is an effective fasciolicidal drug. IL-1 may be involved in disease immunopathogenesis and the depressed IL-4 may be a phenomenon of parasite immune suppression. Complete decline of total IgE is not an early criterion of cure.
Massoud
Ahmed M A
AM
Department of Tropical Medicine, Faculty of Medicine for Boys, Al-Azhar University, Nast City, Cairo, Egypt.
El-Kholy
Naglaa M B
NM
El-Shennawy
Farha A
FA
Farag
Raghda E
RE
D000293:Adolescent; D000328:Adult; D000818:Animals; D000980:Antiplatyhelmintic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D029744:Commiphora / Q000737:chemistry*; D005209:Fasciola / Q000276:immunology*; D005211:Fascioliasis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome
D000980:Antiplatyhelmintic Agents; D007375:Interleukin-1; D010936:Plant Extracts; D015847:Interleukin-4